November 5, 2015
2 pm to 3 pm EST
We will describe the use of single molecule arrays (Simoa) for the multiplex detection of proteins at very low concentrations. We will provide an overview of the Simoa technology - which is capable of providing a 1000-fold improvement in sensitivity
to proteins over conventional assays - and describe how it can be used to detect multiple proteins at the single molecule level. We will introduce Simoa 2.0, our next generation Simoa system that is faster, more robust, and easier to use, that
will enable researchers to tackle an even broader range of applications requiring sensitivity, multiplexing, and automation. The presentation will highlight the development of next generation assay protocols with greater robustness; an enhanced,
more user-friendly software interface; 21 CFR Part 11 Compliant Software; reduced sample volumes; and an expanded menu, including multiplex panels and multiplex homebrew. The growing recent body of research in applications of Simoa that have enabled
unique measurements of proteins across the biomedical arena, including neurology, immuno-oncology, PK/PD, cardiovascular disease, and infectious diseases, will also be highlighted. The Chairman and CEO of Quanterix, Kevin Hrusovsky, will also
share his vision for the company and how the Simoa 2.0 technology has the potential to change today's "sick care" into true health care of the future. In his comments, Kevin will explain how he has reshaped and relaunched the company around Simoa
2.0 to be completely focused around supporting and empowering the incredible research the company's customers are engaging in.
- How Simoa 2.0 improves upon the revolutionary ultrasensitive single-molecule Simoa technology
- How key changes to Simoa 2.0 assay protocols that deliver even more robust and precise assays
- How the new software powering Simoa 2.0 enchances useability and supports 21 CFR Part 11 Compliance
- How engineering innovations in Simoa 2.0 reduce sample volumes dramatically
- How Quanterix has grown and re-shaped itself around the Simoa 2.0 launch with changes to training, customer support, and all other functions to be even more committed and focused on its customers
David Duffy, Ph.D.
Vice President, Research and Chief Technology Officer
Dr. Duffy joined Quanterix in 2007 and leads the team of scientists developing its single molecule detection technology. Dr. Duffy was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There he oversaw the development
of a novel chemical technology for optimizing the PK/PD of small molecules that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, Dr. Duffy was at Gamera Biosciences where he was a co-inventor of a centrifugal
microfluidic device called the LabCD that was acquired and commercialized by Tecan. Dr. Duffy is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis. Dr. Duffy was
a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. He was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge. Dr. Duffy obtained his Ph.D. in physical chemistry
from the Department of Chemistry at the University of Cambridge, and his B.A. and M.A. degrees in Natural Sciences from Selwyn College, University of Cambridge.
Executive Chairman & Chief Executive Officer
Kevin is Chief Executive Officer and Executive Chairman of Quanterix. In addition, he serves on the boards of several other technology companies focused on transforming the practices medicine and healthcare. Prior to Quanterix, he was President
of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences (now PerkinElmer); and CEO of Zymark Corporation. Earlier Hrusovsky was President of FMC Pharmaceuticals and International Agricultural Products and held numerous
management positions at DuPont. Hrusovsky currently serves on the Board of Directors of Quanterix, 908 Devices, SynapDx and Solect Energy. He also serves on Educational Board of the Massachusetts Biotech Council, the Advisory Committee for
the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. He formerly served on the boards of SeraCare (now
Linden Partners), Caliper Life Sciences (now PKI), Xenogen – XGEN (now PKI) and Alliant Medical Technology. Kevin received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University. He is the 2013
Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions in life sciences and personal medicine.
Cost: No cost!
Schedule conflict? Register and you'll receive a copy of the recording!